TB Alliance
Kathleen Schostack has a diverse work experience in the pharmaceutical industry. Kathleen served as the Vice President of Program and Alliance Management at TB Alliance, where they successfully led complex initiatives and managed collaborations with major pharmaceutical partners. Prior to that, they worked at Bayer as the Global Program Head in Oncology, providing strategic leadership for global teams in late-stage development. Kathleen also represented Bayer in joint collaboration committees and played a key role in the development of biomarker strategies. Earlier in their career, Kathleen worked at Roche Pharmaceuticals as a Project Leader, Group Director of Technical Regulatory Affairs, and Research Leader in Analytical R&D. In these roles, they demonstrated their expertise in project management, strategic planning, risk management, and regulatory affairs.
Kathleen Schostack has a Bachelor of Science (BS) degree in Medical Technology from Penn State University. Kathleen also holds a Doctor of Philosophy (PhD) degree in Analytical Chemistry and a Master of Science (MS) degree in Biochemistry, both from Stevens Institute of Technology.
TB Alliance
We envision a world where no one dies of tuberculosis. However, this cannot be achieved without improved, faster-acting, and affordable tuberculosis drug regimens that are available to all who need them. These new cures can bring renewed health, hope, and prosperity to millions. Since our inception in 2000, TB Alliance has led the global search for and development of new TB regimens, catalyzing the field and convening cross-sector partnerships to forge the progress that is urgently needed for better TB treatments.